Sign in

MOLN on Nasdaq

Molecular Partners

Logo: molecularpartners.com5

Biopharmaceutical company based in Zürich, Switzerland, founded in 20041

Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.3 Its shares trade on Nasdaq under the symbol MOLN.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

-61.7MNet income, fiscal 20256
2004Founded1

Compare with another stock.

  • TickerMOLN on Nasdaq1
  • Industrybiotechnology1
  • HeadquartersSchlieren1
  • Websitewww.molecularpartners.com
  • Incorporated inSwitzerland7
  • Business addressWagistrasse 14, Schlieren-Zurich, V8 89527
  • Filer categoryNon-accelerated filer, Emerging growth company7
  • Legal formCompany limited by shares4
  • LEI875500AXMLDAZ4D217444
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressWagistrasse 14, 8952 Schlieren, Switzerland4
  • Registered withMinistry of Justice, CHE-112.115.1364

See how the biggest companies compare on our leaderboards

Molecular Partners image from its website
Image: molecularpartners.com9

Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in CHF, the currency the company reports in.

Key numbers, fiscal 2024

-1231.7%Operating margin6
-1087.4%Net margin6
-29.4%Revenue growth, 202410
-38.2%Return on equity6
-60.0M CHFFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Research and development73¢48.6M CHF
  • Selling, general and admin27¢17.6M CHF
  • Interest0¢38.0K CHF
  • Income tax0¢2.0K CHF

Out of 5.0M CHF in revenue.106 The company lost money this year.

Financial statements

Revenue111213105.0M CHF in 2024−76% since 2019
050.0M CHF100.0M CHF150.0M CHF200.0M CHF2019: 20.4M CHF20.4M CHF20192020: 9.3M CHF9.3M CHF2020−54%2021: 9.8M CHF9.8M CHF2021+4%2022: 189.6M CHF189.6M CHF2022+1844%2023: 7.0M CHF7.0M CHF2023−96%2024: 5.0M CHF5.0M CHF2024−29%
Operating income111213106-61.2M CHF in 2024+67% since 2019
-100.0M CHF-50.0M CHF050.0M CHF100.0M CHF150.0M CHF2019: -36.7M CHF-36.7M CHF20192020: -58.3M CHF-58.3M CHF2020+59%2021: -63.4M CHF-63.4M CHF2021+9%2022: 116.6M CHF116.6M CHF20222023: -61.1M CHF-61.1M CHF20232024: -61.2M CHF-61.2M CHF2024+0%
Net income111213106-54.0M CHF in 2024+49% since 2019
-100.0M CHF-50.0M CHF050.0M CHF100.0M CHF150.0M CHF2019: -36.3M CHF-36.3M CHF20192020: -62.8M CHF-62.8M CHF2020+73%2021: -63.8M CHF-63.8M CHF2021+2%2022: 117.9M CHF117.9M CHF20222023: -62.0M CHF-62.0M CHF20232024: -54.0M CHF-54.0M CHF2024−13%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-12-312024-12-312023-12-31
Revenues from research and development collaborations0 CHF5.0M CHF7.0M CHF
Research and development expenses-40.2M CHF-48.6M CHF-48.8M CHF
Selling, general and administrative expenses-15.2M CHF-17.6M CHF-19.4M CHF
Restructuring expenses-2.7M CHF0 CHF0 CHF
Total operating expenses-58.1M CHF-66.2M CHF-68.1M CHF
Operating result-58.1M CHF-61.2M CHF-61.1M CHF
Financial income1.5M CHF7.2M CHF4.3M CHF
Financial expenses-5.0M CHF-38.0K CHF-5.2M CHF
Net finance result-3.5M CHF7.2M CHF-876.0K CHF
Result before income taxes-61.6M CHF-54.0M CHF-62.0M CHF
Income taxes-2.0K CHF-2.0K CHF0 CHF
Net result, attributable to shareholders-61.7M CHF-54.0M CHF-62.0M CHF
Remeasurement of net pension liabilities-3.8M CHF-485.0K CHF-2.0M CHF
Exchange differences on translating foreign operations5.0K CHF-10.0K CHF-16.0K CHF
Other comprehensive result, net of tax-3.8M CHF-495.0K CHF-2.0M CHF
Total comprehensive result, attributable to shareholders-65.5M CHF-54.5M CHF-64.0M CHF
Basic net result per share (in CHF per share)-1.65 CHF-1.59 CHF-1.89 CHF
Diluted net result per share (in CHF per share)-1.65 CHF-1.59 CHF-1.89 CHF

Compare Molecular Partners with another company

Corporate structure

Molecular Partners sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Molecular Partners

  • Molecular Partners Schlieren, Switzerland

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Molecular Partners reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents82.7M CHF6 Dec 31, 202563.9M CHF6 Dec 31, 2024+29.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)2.0K CHF6 Dec 31, 202549.0K CHF6 Dec 31, 2024−95.9%

The story

Researchers at the University of Zürich, Switzerland formed Molecular Partners AG in 2004 while studying monoclonal antibodies. These scientists discovered and developed the DARPin technology and launched the company using this platform.

Molecular Partners became a publicly traded company in November 2014, when it was listed on the SIX Swiss Exchange (ticker MOLN).

Since July 2021, the company is also listed on the Nasdaq in the US under the ticker symbol MOLN.

From Wikipedia’s article on Molecular Partners, shared under CC BY-SA 4.0.8

Products and brands

Molecular Partners has negotiated three agreements with Allergan to develop therapies for ophthalmology (including abicipar), one in 2011 and two in 2012. In 2011, the company licensed its lead asset back then, abicipar, to Allergan. In 2012, Molecular Partners and Allergan expanded their relationship by signing two separate new agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.

Since the company's inception in 2004, Molecular Partners licensed additional DARPin candidates to other leading international pharmaceutical companies, such as Amgen, Roche or Janssen.

In October 2020, as part of a joint venture to develop therapeutic drugs to combat COVID-19, the Swiss pharmaceutical giant Novartis bought 6% of all shares outstanding in Molecular Partners at 23CHF a share.

From Wikipedia’s article on Molecular Partners, shared under CC BY-SA 4.0.8

Timeline

  1. 2004Founded Founded1

Calendar

Coming up

  1. Oct 29, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported ($0.41) a share, on Oct 30, 2025.14

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

92 filings to the SEC since October 2021: 5 annual reports, 8 large holders, 79 other. The latest 20:

  1. Aug 25, 20266-K EDGAR
  2. Jul 20, 20266-K EDGAR
  3. Jul 7, 20266-K EDGAR
  4. Jul 2, 20266-K EDGAR
  5. Jun 24, 2026S-8 EDGAR
  6. Jun 1, 20266-K EDGAR
  7. May 12, 20266-K EDGAR
  8. May 1, 20266-K EDGAR
  9. Apr 14, 20266-K EDGAR
  10. Mar 30, 20266-K EDGAR
  11. Mar 13, 20266-K EDGAR
  12. Mar 12, 20266-K EDGAR
  13. Mar 12, 202620-F EDGAR
  14. Feb 2, 20266-K EDGAR
  15. Jan 12, 20266-K EDGAR
  16. Dec 8, 20256-K EDGAR
  17. Nov 12, 20256-K EDGAR
  18. Oct 30, 20256-K EDGAR
  19. Aug 25, 20256-K EDGAR
  20. Jul 17, 2025SCHEDULE 13G EDGAR

The 92 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Montanova Capital, LLC2,221,494$8.6M0.2%No change
Bvf Inc/il1,353,968$5.1M0.1%No change
Citadel Advisors LLC17,179$65.3K0.0%New
Morgan Stanley367$1.4K0.0%No change
UBS Group AG279$1.1K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Molecular Partners is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMOLECULAR PARTNERS AG2
  • CIK0001745114
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company18
  • Incorporated inSwitzerland18
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business addressWagistrasse 14, Schlieren-Zurich, V8 89522
  • Phone41 44 755 77 002
  • Shares outstanding40,374,641 shares as of Dec 31, 202518
  • AuditorKPMG AG, Zurich, Switzerland PCAOB ID 3240; no auditor attestation of internal control over financial reporting18
  • On EDGAR sinceMar 15, 20212
  • Filings120 in all: 6-K (67), CORRESP (7), 20-F (5), F-1/A (5), UPLOAD (5), EFFECT (4), S-8 (4), SC 13G/A (4)2
    All 23 form types

    6-K/A (2), F-3 (2), SCHEDULE 13G (2), SEC STAFF LETTER (2), 424B4 (1), 424B5 (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-6 (1), FWP (1), SC 13D (1), SC 13D/A (1), SC 13G (1)

  • Latest filingsAnnual report (20-F) Mar 12, 2026

Securities registered for trading

ClassSymbolExchange
American depositary shares (each representingone ordinary share, CHF 0.10 nominal value per share)MOLNThe Nasdaq Stock Market LLC
Ordinary shares, CHF 0.10 nominal value per shareThe Nasdaq Stock Market LLC

From the cover page of the 20-F filed Mar 12, 2026 (Section 12(b) of the Exchange Act).18

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18